Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 12, 2012

NovAliX to Use Graffinity Screening Platform in Drug Discovery Deal with Teijin Pharma

  • NovAliX will use its Graffinity SPR-based screening platform in a drug discovery program of Teijin Pharma. NovAliX will use the technology to identify novel chemotypes, and then apply its native nano-MS technology to further characterize selected small molecule hit structures.

    Under the multitarget drug discovery collaboration, French-owned NovAliX said it will receive technology access fees as well as further research funding payments from the collaboration, its first with Teijin but its second with a Japanese pharmaceutical company.

    NovAliX-owned Graffinity Pharmaceuticals announced in March 2011 that it would apply the fragment based screening platform to a drug discovery program of Shionogi & Co., in return for unspecified technology access fees and payments.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »